EPA/DHA (Omega 3) Market 2026-2035
Description
Global EPA/DHA (Omega 3) Market Size, Share & Trends Analysis Report By Source (Anchovy/Sardine Oil, High Concentrates, Medium Concentrates, Low Concentrates, Algae Oil, Tuna Oil, Cod Liver Oil, Salmon Oil, Krill Oil, and Menhaden Oil), By Application (Dietary supplements, Pharmaceuticals, Functional Foods, Pet & Animal Feed, and Infant Formulas) Forecast Period (2026-2035)
Industry Overview
EPA/DHA (omega 3) market valued at $10,400.1 million in 2025 and is projected to reach $17,294.0 million by 2035, growing at a CAGR of 5.8% during the forecast period (2026-2035). The global EPA/DHA (omega-3) market is expanding steadily as consumers and healthcare providers increasingly recognize the role of essential fatty acids in cardiovascular, cognitive, and metabolic health. Growth is being reinforced by rising demand for preventive nutrition, functional foods, and dietary supplements enriched with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Expanding clinical research supporting omega-3 benefits in heart health, maternal nutrition, and inflammatory conditions is further strengthening market adoption. As regulatory authorities and health organizations promote nutritional awareness and evidence-based supplementation, EPA/DHA products are becoming integral to global wellness and therapeutic nutrition strategies.
Market Dynamics
Rising Demand for Preventive and Functional Nutrition
Consumers are increasingly shifting toward preventive healthcare approaches, driving strong demand for omega-3 fortified supplements, infant formula, and functional beverages. EPA and DHA are widely incorporated into products targeting cardiovascular health, brain development, and healthy aging. Manufacturers are focusing on high-purity, sustainably sourced formulations to meet growing quality expectations. As lifestyle-related disorders continue to rise globally, omega-3 supplementation is becoming a core component of daily health management.
Growing Innovation in Algal and Sustainable Omega-3 Sources
Sustainability concerns surrounding marine fish oil sourcing are accelerating innovation in algal-based and plant-derived omega-3 production. Companies are investing in advanced extraction technologies and fermentation-based processes to ensure consistent supply and environmental compliance. Algal DHA is witnessing strong adoption in infant nutrition and vegan supplements. These advancements are diversifying raw material sources while enhancing long-term supply chain stability, supporting sustained market growth.
Market Segmentation
Anchovy and sardine oil represent the largest share of the global EPA/DHA (Omega-3) market, supported by their high natural concentration of omega-3 fatty acids and established supply chains. These small pelagic fish are widely used due to their favourable EPA and DHA profiles, cost efficiency, and large-scale availability, particularly in key fishing regions. Manufacturers prefer anchovy and sardine oil for producing both standard and concentrated omega-3 formulations used across dietary supplements and pharmaceutical applications. In addition, advancements in purification technologies and sustainability certifications are strengthening consumer confidence and supporting continued dominance of this segment.
Dietary Supplements Segment to Drive Application Demand
Based on application, dietary supplements account for the largest share of the EPA/DHA market, driven by growing consumer awareness of the cardiovascular, cognitive, and joint health benefits associated with omega-3 intake. Rising health consciousness, aging populations, and preventive healthcare trends are fueling demand for fish oil capsules, soft gels, and fortified products worldwide. The expansion of e-commerce channels and direct-to-consumer nutraceutical brands is further enhancing product accessibility. As consumers increasingly prioritize daily nutritional supplementation, the dietary supplements segment continues to anchor overall market growth and maintain a leading position within the global EPA/DHA market.
Regional Outlook
The global EPA/DHA (omega 3) market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Expanding Nutraceutical Adoption Across Asia-Pacific
Asia-Pacific is experiencing robust growth in the EPA/DHA market due to rising disposable incomes, expanding middle-class populations, and increasing awareness of dietary supplementation. Growing demand for fortified foods, maternal nutrition products, and pediatric supplements is contributing to regional expansion. Governments and health authorities are also promoting nutrition awareness campaigns, further encouraging omega-3 intake. With expanding retail distribution channels and e-commerce penetration, the region continues to present strong growth potential.
North America Region Dominates the Market with Major Share
North America maintains a substantial share of the global EPA/DHA market, supported by high consumer awareness and established dietary supplement consumption patterns. The region benefits from strong regulatory oversight, product innovation, and wide availability across pharmacies, supermarkets, and online platforms. Continuous clinical research and marketing efforts promoting heart and cognitive health benefits further sustain demand. Combined with a mature nutraceutical industry ecosystem, these factors reinforce North America’s leading position.
Market Players Outlook
The major companies operating in the global EPA/DHA (omega 3) market include Aker BioMarine ASA, BASF SE, Corbion N.V., Croda International Plc, DSM-Firmenich AG, among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
Industry Overview
EPA/DHA (omega 3) market valued at $10,400.1 million in 2025 and is projected to reach $17,294.0 million by 2035, growing at a CAGR of 5.8% during the forecast period (2026-2035). The global EPA/DHA (omega-3) market is expanding steadily as consumers and healthcare providers increasingly recognize the role of essential fatty acids in cardiovascular, cognitive, and metabolic health. Growth is being reinforced by rising demand for preventive nutrition, functional foods, and dietary supplements enriched with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Expanding clinical research supporting omega-3 benefits in heart health, maternal nutrition, and inflammatory conditions is further strengthening market adoption. As regulatory authorities and health organizations promote nutritional awareness and evidence-based supplementation, EPA/DHA products are becoming integral to global wellness and therapeutic nutrition strategies.
Market Dynamics
Rising Demand for Preventive and Functional Nutrition
Consumers are increasingly shifting toward preventive healthcare approaches, driving strong demand for omega-3 fortified supplements, infant formula, and functional beverages. EPA and DHA are widely incorporated into products targeting cardiovascular health, brain development, and healthy aging. Manufacturers are focusing on high-purity, sustainably sourced formulations to meet growing quality expectations. As lifestyle-related disorders continue to rise globally, omega-3 supplementation is becoming a core component of daily health management.
Growing Innovation in Algal and Sustainable Omega-3 Sources
Sustainability concerns surrounding marine fish oil sourcing are accelerating innovation in algal-based and plant-derived omega-3 production. Companies are investing in advanced extraction technologies and fermentation-based processes to ensure consistent supply and environmental compliance. Algal DHA is witnessing strong adoption in infant nutrition and vegan supplements. These advancements are diversifying raw material sources while enhancing long-term supply chain stability, supporting sustained market growth.
Market Segmentation
- Based on the source, the market is segmented into anchovy/sardine oil, high concentrates, medium concentrates, low concentrates, algae oil, tuna oil, cod liver oil, salmon oil, krill oil, and menhaden oil.
- Based on the application, the market is segmented into dietary supplements, pharmaceuticals, functional foods, pet & animal feed, and infant formulas.
Anchovy and sardine oil represent the largest share of the global EPA/DHA (Omega-3) market, supported by their high natural concentration of omega-3 fatty acids and established supply chains. These small pelagic fish are widely used due to their favourable EPA and DHA profiles, cost efficiency, and large-scale availability, particularly in key fishing regions. Manufacturers prefer anchovy and sardine oil for producing both standard and concentrated omega-3 formulations used across dietary supplements and pharmaceutical applications. In addition, advancements in purification technologies and sustainability certifications are strengthening consumer confidence and supporting continued dominance of this segment.
Dietary Supplements Segment to Drive Application Demand
Based on application, dietary supplements account for the largest share of the EPA/DHA market, driven by growing consumer awareness of the cardiovascular, cognitive, and joint health benefits associated with omega-3 intake. Rising health consciousness, aging populations, and preventive healthcare trends are fueling demand for fish oil capsules, soft gels, and fortified products worldwide. The expansion of e-commerce channels and direct-to-consumer nutraceutical brands is further enhancing product accessibility. As consumers increasingly prioritize daily nutritional supplementation, the dietary supplements segment continues to anchor overall market growth and maintain a leading position within the global EPA/DHA market.
Regional Outlook
The global EPA/DHA (omega 3) market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Expanding Nutraceutical Adoption Across Asia-Pacific
Asia-Pacific is experiencing robust growth in the EPA/DHA market due to rising disposable incomes, expanding middle-class populations, and increasing awareness of dietary supplementation. Growing demand for fortified foods, maternal nutrition products, and pediatric supplements is contributing to regional expansion. Governments and health authorities are also promoting nutrition awareness campaigns, further encouraging omega-3 intake. With expanding retail distribution channels and e-commerce penetration, the region continues to present strong growth potential.
North America Region Dominates the Market with Major Share
North America maintains a substantial share of the global EPA/DHA market, supported by high consumer awareness and established dietary supplement consumption patterns. The region benefits from strong regulatory oversight, product innovation, and wide availability across pharmacies, supermarkets, and online platforms. Continuous clinical research and marketing efforts promoting heart and cognitive health benefits further sustain demand. Combined with a mature nutraceutical industry ecosystem, these factors reinforce North America’s leading position.
Market Players Outlook
The major companies operating in the global EPA/DHA (omega 3) market include Aker BioMarine ASA, BASF SE, Corbion N.V., Croda International Plc, DSM-Firmenich AG, among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In June 2025, DSM-Firmenich expanded its algal-based DHA production capacity to meet growing global demand for sustainable omega-3 ingredients in infant formula and dietary supplements.
- In February 2025, BASF SE introduced a high-concentration EPA/DHA omega-3 ingredient designed for cardiovascular-focused nutraceutical formulations, aiming to enhance purity and bioavailability standards in the market.
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global EPA/DHA (omega 3) market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
Table of Contents
293 Pages
- 1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global EPA/DHA (Omega 3) Market Sales Analysis – Source Application ($ Million)
- EPA/DHA (Omega 3) Market Sales Performance of Top Countries
- 1.1. Research Methodology
- Primary Research Approach
- Secondary Research Approach
- 1.2. Market Snapshot
- 2. Market Overview and Insights
- 2.1. Scope of the Study
- 2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key EPA/DHA (Omega 3) Market Trends
- 2.2.2. Market Recommendations
- 2.3. Porter's Five Forces Analysis for the EPA/DHA (Omega 3) Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes
- 3. Market Determinants
- 3.1. Market Drivers
- 3.1.1. Drivers For Global EPA/DHA (Omega 3) Market: Impact Analysis
- 3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global EPA/DHA (Omega 3) Market: Impact Analysis
- 3.3. Market Opportunities
- 3.3.1. Opportunities For Global EPA/DHA (Omega 3) Market: Impact Analysis
- 4. Competitive Landscape
- 4.1. Competitive Dashboard – EPA/DHA (Omega 3) Market Revenue and Share by Manufacturers
- EPA/DHA (Omega 3) Product Comparison Analysis
- Top Market Player Ranking Matrix
- 4.2. Key Company Analysis
- 4.2.1. Aker BioMarine ASA
- 4.2.1.1. Overview
- 4.2.1.2. Product Portfolio
- 4.2.1.3. Financial Analysis
- 4.2.1.4. SWOT Analysis
- 4.2.1.5. Business Strategy
- 4.2.2. BASF SE
- 4.2.2.1. Overview
- 4.2.2.2. Product Portfolio
- 4.2.2.3. Financial Analysis
- 4.2.2.4. SWOT Analysis
- 4.2.2.5. Business Strategy
- 4.2.3. Corbion N.V.
- 4.2.3.1. Overview
- 4.2.3.2. Product Portfolio
- 4.2.3.3. Financial Analysis
- 4.2.3.4. SWOT Analysis
- 4.2.3.5. Business Strategy
- 4.2.4. Croda International Plc
- 4.2.4.1. Overview
- 4.2.4.2. Product Portfolio
- 4.2.4.3. Financial Analysis
- 4.2.4.4. SWOT Analysis
- 4.2.4.5. Business Strategy
- 4.2.5. DSM-Firmenich AG
- 4.2.5.1. Overview
- 4.2.5.2. Product Portfolio
- 4.2.5.3. Financial Analysis
- 4.2.5.4. SWOT Analysis
- 4.2.5.5. Business Strategy
- 4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration
- 5. Global EPA/DHA (Omega 3) Market Sales Analysis by Type ($ Million)
- 5.1. Anchovy/Sardine Oil
- 5.2. High Concentrates
- 5.3. Medium Concentrates
- 5.4. Low Concentrates
- 5.5. Algae Oil
- 5.6. Tuna Oil
- 5.7. Cod Liver Oil
- 5.8. Salmon Oil
- 5.9. Krill Oil
- 5.10. Menhaden Oil
- 6. Global EPA/DHA (Omega 3) Market Sales Analysis by Application ($ Million)
- 6.1. Dietary supplements
- 6.2. Pharmaceuticals
- 6.3. Functional Foods
- 6.4. Pet & Animal Feed
- 6.5. Infant Formulas
- 7. Regional Analysis
- 7.1. North American EPA/DHA (Omega 3) Market Sales Analysis – Source Application Country ($ Million)
- Macroeconomic Factors for North America
- 7.1.1. United States
- 7.1.2. Canada
- 7.2. European EPA/DHA (Omega 3) Market Sales Analysis – Source Application Country ($ Million)
- Macroeconomic Factors for Europe
- 7.2.1. UK
- 7.2.2. Germany
- 7.2.3. Italy
- 7.2.4. Spain
- 7.2.5. France
- 7.2.6. Russia
- 7.2.7. Rest of Europe
- 7.3. Asia-Pacific EPA/DHA (Omega 3) Market Sales Analysis – Source Application Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- 7.3.1. China
- 7.3.2. Japan
- 7.3.3. South Korea
- 7.3.4. India
- 7.3.5. Australia & New Zealand
- 7.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 7.3.7. Rest of Asia-Pacific
- 7.4. Rest of the World EPA/DHA (Omega 3) Market Sales Analysis – Source Application Country ($ Million)
- Macroeconomic Factors for Rest of the World
- 7.4.1. Latin America
- 7.4.2. Middle East and Africa
- 8. Company Profiles
- 8.1. Aker BioMarine Antarctic AS
- 8.1.1. Quick Facts
- 8.1.2. Company Overview
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategies
- 8.2. Alaska Omega
- 8.2.1. Quick Facts
- 8.2.2. Company Overview
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategies
- 8.3. American Marine Ingredients
- 8.3.1. Quick Facts
- 8.3.2. Company Overview
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategies
- 8.4. BASF SE
- 8.4.1. Quick Facts
- 8.4.2. Company Overview
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategies
- 8.5. Bioriginal Food & Science Corporation
- 8.5.1. Quick Facts
- 8.5.2. Company Overview
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategies
- 8.6. Cargill, Incorporated
- 8.6.1. Quick Facts
- 8.6.2. Company Overview
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategies
- 8.7. Copeinca ASA
- 8.7.1. Quick Facts
- 8.7.2. Company Overview
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategies
- 8.8. Corbion N.V.
- 8.8.1. Quick Facts
- 8.8.2. Company Overview
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategies
- 8.9. Croda International Plc
- 8.9.1. Quick Facts
- 8.9.2. Company Overview
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategies
- 8.10. DSM-Firmenich AG
- 8.10.1. Quick Facts
- 8.10.2. Company Overview
- 8.10.3. Product Portfolio
- 8.10.4. Business Strategies
- 8.11. Epax AS
- 8.11.1. Quick Facts
- 8.11.2. Company Overview
- 8.11.3. Product Portfolio
- 8.11.4. Business Strategies
- 8.12. GC Rieber Oils AS
- 8.12.1. Quick Facts
- 8.12.2. Company Overview
- 8.12.3. Product Portfolio
- 8.12.4. Business Strategies
- 8.13. Golden Omega S.A.
- 8.13.1. Quick Facts
- 8.13.2. Company Overview
- 8.13.3. Product Portfolio
- 8.13.4. Business Strategies
- 8.14. KD Pharma Group
- 8.14.1. Quick Facts
- 8.14.2. Company Overview
- 8.14.3. Product Portfolio
- 8.14.4. Business Strategies
- 8.15. Koninklijke DSM N.V.
- 8.15.1. Quick Facts
- 8.15.2. Company Overview
- 8.15.3. Product Portfolio
- 8.15.4. Business Strategies
- 8.16. Nissui Pharmaceutical Co., Ltd.
- 8.16.1. Quick Facts
- 8.16.2. Company Overview
- 8.16.3. Product Portfolio
- 8.16.4. Business Strategies
- 8.17. Nutreco N.V.
- 8.17.1. Quick Facts
- 8.17.2. Company Overview
- 8.17.3. Product Portfolio
- 8.17.4. Business Strategies
- 8.18. Omega Protein Corporation
- 8.18.1. Quick Facts
- 8.18.2. Company Overview
- 8.18.3. Product Portfolio
- 8.18.4. Business Strategies
- 8.19. Pelagia AS
- 8.19.1. Quick Facts
- 8.19.2. Company Overview
- 8.19.3. Product Portfolio
- 8.19.4. Business Strategies
- 8.20. Pharma Marine AS
- 8.20.1. Quick Facts
- 8.20.2. Company Overview
- 8.20.3. Product Portfolio
- 8.20.4. Business Strategies
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
